Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.
Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.
To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
Troponin has become a widely accepted cardiac biomarker for myocardial infarction patients admitted to emergency rooms. But just how reliable is troponin in determining if a heart attack is really a heart attack?
In an era of clinician shortages, those living in rural areas are at risk of not receiving needed care. Cardiologists are stepping up, but will it be enough?
In the U.S., candidates for heart transplantation are prioritized by the intensity of treatment they’ve received, potentially leading some centers to overtreat patients.
